http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Hyung Soon,Choi, Gi Hong,Choi, Jin Sub,Kim, Kyung Sik,Han, Kwang-Hyub,Seong, Jinsil,Ahn, Sang Hoon,Kim, Do Young,Park, Jun Yong,Kim, Seung Up,Kim, Beom Kyung Raven Press 2014 Annals of Surgical Oncology Vol.21 No.11
<P>This study evaluated the down-staging efficacy and impact on resectability of concurrent chemoradiotherapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in locally advanced hepatocellular carcinoma, and identified prognostic factors of disease-free survival (DFS) and overall survival (OS) after curative resection.</P>
Lee, Yu-Jin,Chung, Da-Jung,Oh, Sang-Hyub,Choi, Seong-Ho Hindawi Limited 2012 Journal of nanomaterials Vol.2012 No.-
<P>A biosensor comprising<I>tyrosinase</I>immobilized on bifunctionalized multiwalled carbon nanotube (MWNT) supports was prepared for the detection of phenolic compounds in drinks such as red wine and juices. The MWNT supports were prepared by radiation-induced graft polymerization (RIGP) of epoxy-containing glycidyl methacrylate (GMA), to covalently immobilize the<I>tyrosinase</I>, and vinyl ferrocene (VF), which can act as an electron transfer mediator via redox reactions. The bifunctionalized MWNTs were characterized by X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), and thermogravimetric analysis (TGA). Electrodes prepared with the MWNTs showed increased current with increasing VF content. A biosensor comprising<I>tyrosinase</I>immobilized on the bifunctionalized MWNTs could detect phenol at 0.1–20 mM. Phenolics in red wine and juices were determined using the biosensor after its calibration.</P>
Sang Hyub Lee,이철희,박인성,한종우 대한뇌혈관외과학회 2018 Journal of Cerebrovascular and Endovascular Neuros Vol.20 No.1
A 50-year-old woman reported to the emergency department with thunderclap headache and vomiting. Non-enhanced brain computed tomography (CT) showed a subarachnoid hemorrhage of Hunt-Hess Grade II and Fisher Grade III. Brain angiography CT and transfemoral cerebral angiography (TFCA) revealed an aneurysm of the anterior communicating artery. A direct neck clipping was performed using the pterional approach. The post-operation CT was uneventful. Six days postoperatively, the patient became lethargic. The mean velocity (cm/s) of the middle cerebral artery peaked at 173 cm/s on the right side and 167 cm/s on the left. A TFCA revealed decreased perfusion in both recurrent arteries of Heubner (RAH), but no occlusion in either. Intra-arterial nimodipine injection was administered. On the 7th postoperative day, CT demonstrated a newly developed low-density lesion in the RAH territory bilaterally. The cause of the infarction was attributed to decreased perfusion caused by cerebral vasospasm. The patient was discharged with no definite neurologic deficit except for mild cognitive disorder.
Sang Hyub Lee,박인성,이자명,이광호,Hyun Park,이철희 대한뇌혈관외과학회 2018 Journal of Cerebrovascular and Endovascular Neuros Vol.20 No.1
Objective : The aim of this study was to evaluate the safety and efficacy of stent-assisted coil embolization using only a glycoprotein IIb/IIIa inhibitor (tirofiban). Materials and Methods : We retrospectively reviewed patients with a subarachnoid hemorrhage due to ruptured wide-necked intracranial aneurysms who were treated by stent-assisted coil embolization. In all patients, the glycoprotein IIb/IIIa inhibitor tirofiban was administered just before stent deployment. Electronic medical records for these patients were reviewed for peri-procedural complications and extra-ventricular drainage catheter related hemorrhage, as well as Glasgow outcome scale (GOS) at discharge, 3 months, and 6 months follow-up were recorded. Results : Fifty-one aneurysms in 50 patients were treated. The mean patient age was 64.9 years. Eighteen patients (36%) received a World Federation of Neurosurgical Societies grade of 4 or 5. The mean aneurysm size was 9.48 mm and mean dome-to-neck ratio was 1.06. No intraoperative aneurysm ruptures occurred, although five (10%) episodes of asymptomatic stent thrombosis did occur. Three patients experienced a delayed thrombo-embolic event and two a delayed hemorrhagic event. Immediate radiologic assessment indicated a complete occlusion in 29 patients, a residual neck in 19, and a residual sac in 3. Four patients (8%) died. Sixteen patients (32%) experienced a poor GOS (< 4). Two aneurysms were recanalized during the follow-up period (mean, 19 months for clinical and 18 months for angiographic follow-up). Conclusion : Treatment of ruptured wide-necked intracranial aneurysms via stent-assisted coil embolization with a glycoprotein IIb/IIIa inhibitor alone was found to be relatively safe and efficient.
Lee, Jung Min,Kim, Hyung Joon,Park, Jun Yong,Lee, Chun Kyon,Kim, Do Young,Kim, Ja Kyung,Lee, Hyun Woong,Paik, Yong Han,Lee, Kwan Sik,Han, Kwang-Hyub,Chon, Chae Yoon,Hong, Sun Pyo,Nguyen, Tin,Ahn, Sang International Medical Press 2009 ANTIVIRAL THERAPY Vol.14 No.5
<P>BACKGROUND: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. METHODS: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. RESULTS: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351), HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%), IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. CONCLUSIONS: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.</P>